Christopher Yea Net Worth & Insider Trades
Christopher Yea - Chief Development Officer, Kalvista Pharmaceuticals, Inc
What is Christopher Yea's Net Worth?
The current estimated net worth of Kalvista Pharmaceuticals, Inc's Chief Development Officer, Christopher Yea, is estimated to be about $2.5M . Christopher Yea owns about 33,597 units of Kalvista Pharmaceuticals, Inc common stock. In the last 6 years at Kalvista Pharmaceuticals, Inc, Christopher Yea has sold an estimated value of $1.77M worth.
What is Christopher Yea's Past Insider Trading?
Christopher Yea's largest purchase order was 7,355 units , worth over $31.63 on July 24, 2019. Christopher Yea's largest sale order was 15,000 units , worth over $503.88K on February 25, 2021. In total, Christopher Yea has made about 24 transactions over 6 years of their time at Kalvista Pharmaceuticals, Inc. Christopher Yea usually trades in May, with the busiest year in 2019. The most recent transaction was a sale order of 1,145 units , worth over $17.13K on August 19, 2022.
Christopher Yea
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What was Christopher Yea's Salary in 2021?
As Chief Development Officer of Kalvista Pharmaceuticals, Inc, Christopher Yea has a total base salary of $420,000 . Christopher Yea received compensation valued at about $1,409,401 in 2021 after becoming Chief Development Officer. The vast majority of their compensation came in the form of a bonus of $252,000 , option awards of $712,060 , and other compensation of $25,341 .
What is Christopher Yea's' Mailing Address?
- Mailing address is One Kendall Square, Building 200 Suite 2203 Cambridge MA 02139 MA
Kalvista Pharmaceuticals, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Stock Awards
|
Option Awards
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|
| T. Andrew Crockett | 2021 | $556,120 | $458,799 | - | $1,281,708 | $11,400 | $2,308,027 |
| T. Andrew Crockett | 2020 | $556,120 | $229,400 | - | $1,163,160 | $11,882 | $1,960,562 |
| T. Andrew Crockett | 2019 | $505,000 | $353,500 | - | $2,418,444 | $11,000 | $3,287,944 |
| Benjamin L. Palleiko | 2021 | $435,000 | $261,000 | - | $747,663 | $15,850 | $1,459,513 |
| Benjamin L. Palleiko | 2020 | $435,000 | $156,600 | - | $581,580 | $11,900 | $1,185,080 |
| Benjamin L. Palleiko | 2019 | $366,000 | $192,150 | $527,794 | $994,555 | $11,000 | $2,091,499 |
| Christopher M. Yea | 2021 | $420,000 | $252,000 | - | $712,060 | $25,341 | $1,409,401 |
| Christopher M. Yea | 2020 | $420,000 | $117,600 | - | $480,773 | $25,271 | $1,094,044 |
| Christopher M. Yea | 2019 | $341,093 | $174,596 | - | $891,350 | $20,466 | $1,427,505 |
| No matching records found | |||||||
Source: https://www.sec.gov/Archives/edgar/data/1348911/000119312521249158/d191826ddef14a.htm
What are Kalvista Pharmaceuticals, Inc's Past Insider Trades?
Kalvista Pharmaceuticals, Inc's most recent insider trade came on September 7, 2022 by Andrew Thomas Crockett who sold 7,820 units worth $22.46K . In the last 5 years, insiders at Kalvista Pharmaceuticals, Inc have sold an estimated value of $75.63M and bought an estimated value of $44.2M worth of shares. Insider trading is most common in October, with the busiest year in 2019 and 2021. The most active traders at the company are Andrew Thomas Crockett, CEO, Christopher Yea, Chief Development Officer, and Edward Feener, Chief Scientific Officer .
KalVista Pharmaceuticals, Inc. Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||